HK Stock Market Move | HBM HOLDINGS-B (02142) has risen nearly 15% again as HBM7004's clinical application has been approved by the National Medical Products Administration for the treatment of advanced solid tumors.

HBM HOLDINGS-B (02142) rose nearly 15% again, and as of the time of publication, it had increased by 11.73%, trading at HKD 16.19 with a transaction volume of HKD 278 million. On the news front, HBM Pharmaceuticals announced that the clinical trial application for HBM7004, a new drug for the treatment of advanced solid tumors, has been approved by the National Medical Products Administration. This marks another significant advancement for the company following the announcement on May 8, 2026, that it had received FDA approval for its IND application. It is reported that HBM7004 is a novel B7H4xCD3 bispecific antibody developed from the groups proprietary HBICE platform, providing differentiated solutions for cancer immunotherapy in terms of efficacy and safety. The development of HBM7004 further highlights the flexibility and plug-and-play advantages of the HBICE platform.